ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Warwick, G.
Right arrow Articles by Yates, D. H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Warwick, G.
Right arrow Articles by Yates, D. H.
Eur Respir J 2008; 32:503-512
Copyright ©ERS Journals Ltd 2008

Biomarkers in pulmonary hypertension

G. Warwick1, P. S. Thomas2 and D. H. Yates1

1 Dept of Thoracic Medicine, St Vincent's Hospital, and 2 Inflammatory Diseases Research Unit, University of New South Wales, Sydney, Australia.

CORRESPONDENCE: D. H. Yates, Dept of Thoracic Medicine, St Vincent's Hospital, 390 Victoria Street, Darlinghurst, NSW 2010, Australia. Fax: 61 283822359. E-mail: Deborahy88{at}hotmail.com

Keywords: Asymmetric dimethylarginine, biomarkers, endothelin, natriuretic peptide, pulmonary hypertension

Received: November 28, 2007
Accepted April 3, 2008

There have been significant recent advances in the understanding of the pathophysiology of pulmonary hypertension, and a growing number of therapeutic agents have become available to the treating physician. Traditional methods of diagnosing and monitoring this condition have comprised echocardiography and right heart catheterisation, in addition to functional measures, such as estimation of functional class and the 6-min walk test. An increasing number of biomarkers have been described that are elevated in pulmonary hypertension and which may assist the clinician in diagnosis and in the assessment of disease severity and response to treatment.

The present article details the more important biomarkers, their potential applications and the evidence supporting their use.




This article has been cited by other articles:


Home page
Eur Respir JHome page
A. Chaouat, R. Naeije, and E. Weitzenblum
Pulmonary hypertension in COPD
Eur. Respir. J., November 1, 2008; 32(5): 1371 - 1385.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the European Respiratory Society.